Table 3. Publications reporting TMB and relevant biomarkers.

Publication	Main findings relating to TMB and biomarker	P Value
PD-1/PD-L1
Carbone 2017 [10]	Pearson’s r: 0.059	NA
Choi 2017 [27]	Pearson’s r:
	PD-1: 0.004	PD-1: .96958
	PD-L1: –0.067	PD-L1: .52563
Goldberg 2017 [48]	Spearman’s rho: 0.12	.00035
Liu 2018 [49]	Spearman’s rho: 0.092	.62
Mahadevan 2017 [36]	Undefined	.47
Nakagomi 2018 [50]	Undefined	.49
Schabath 2017 [53]	Undefined	.03
Senarathne 2018 [55]	Undefined	.05
Ross 2017 [45]	Spearman’s rho: 0.085	.00062
EGFR
Chen 2017 [46]	Median TMB higher in EGFR-wt patients (8.4) vs EGFR-mut patients (4.6)	.034
Dong 2017 [47]
TCGA	Median TMB higher in EGFR-wt patients (181) vs EGFR-mut patients (56)	< .001
Broad Institute	Median TMB higher in EGFR-wt patients (209) vs EGFR-mut patients (59)	.003
Guangdong Lung Cancer Institute	Median TMB higher in EGFR-wt patients (197) vs EGFR-mut patients (162)	.029
Owada 2017 [51]	Median TMB higher in EGFR-wt patients vs EGFR-mut patients (values NR)	< .001
TP53
Owada 2017 [51]	Median TMB higher in TP53-positive patients vs TP53-negative patients (values NR)	< .001
Rothberg 2017 [52]	Median TMB higher in TP53-positive patients vs TP53-negative patients (values NR)	< .0001
Schrock 2017 [54]	Median TMB higher in TP53-positive patients (10.1) vs TP53-negative patients (5)	.001

Abbreviations: NR, not reported; PD-1, programmed cell death-1; PD-L1, programmed death ligand 1; TMB, tumor mutational burden.